Význam imunitního systému a možnosti imunoterapie u maligního melanomu
[Importance of the Immune System and Immunotherapeutic Options in Malignant Melanoma]
Language Czech Country Czech Republic Media print
Document type English Abstract, Journal Article, Review
PubMed
26647890
DOI
10.14735/amko20154s56
PII: 56685
- MeSH
- CTLA-4 Antigen antagonists & inhibitors MeSH
- Programmed Cell Death 1 Receptor antagonists & inhibitors MeSH
- Humans MeSH
- Melanoma drug therapy immunology MeSH
- Antibodies, Monoclonal therapeutic use MeSH
- Check Tag
- Humans MeSH
- Publication type
- English Abstract MeSH
- Journal Article MeSH
- Review MeSH
- Names of Substances
- CTLA-4 Antigen MeSH
- Programmed Cell Death 1 Receptor MeSH
- Antibodies, Monoclonal MeSH
- PDCD1 protein, human MeSH Browser
Over the past several years, many important changes in the treatment of metastatic melanoma have occurred. New treatment options have been discovered to exploit inhibition of immune checkpoints for promotion of antitumor immune response. Recent results of clinical studies with anti-CTLA 4 and anti-PD 1 monoclonal antibodies show the ability of immunotherapy to extend progression free survival and overall survival in patients with metastatic melanoma when compared to chemotherapy and other therapeutic methods. This article focuses on efficacy and safety of these immunotherapeutic approaches and considered biomarkers of tumor response.
References provided by Crossref.org
Potential predictors of immunotherapy in small cell lung cancer
